Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients
In December 2024, the FDA approved STEQEYMA in 45mg/0.5mL and 90mg/mL solutions in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL in a single-dose vial for intravenous infusion in adult and pediatric patients 6 years and older with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis.
"Managing inflammatory diseases in pediatric patients can be particularly complex," said Hetal Patel, PharmD MBA, Vice President of Medical Affairs at Celltrion USA. "The new dosage form and strength of STEQEYMA allow us to better meet the specific needs of young patients, giving physicians a valuable treatment option with flexibility, supported by a well-established safety and efficacy profile."
"We are proud to offer a new presentation of STEQEYMA that aligns with the indications of the reference product," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "This approval reinforces our commitment to broadening access for all patient populations, including children aged 6 years and older living with chronic inflammatory conditions. As a company with a strong legacy in immunology, we are dedicated to ensuring broader access and flexibility in care for patients of all ages."
The FDA approval of STEQEYMA was based on the totality of evidence, including the results from a phase III study in adults with moderate to severe plaque psoriasis, in which the primary endpoint was the rate of change in the Psoriasis Area and Severity Index (PASI) for skin symptoms. The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. [2], [3]
The FDA has granted STEQEYMA full interchangeability with STELARA across all indications of STELARA, following the expiration of exclusivity for the first interchangeable biosimilar on April 30, 2025.
Notes to Editors:
About STEQEYMA ® (ustekinumab-stba)
STEQEYMA ®, formerly known as CT-P43, is a human IL-12 and -23 antagonist indicated for multiple immune-mediated diseases. It encompasses all indications approved for the STELARA ® reference product, including psoriasis (PsO), psoriatic arthritis (PsA), Crohn's disease (CD), ulcerative colitis (UC) in adults, and PsO and PsA in pediatric patients 6 years of age and older. STEQEYMA is available in both subcutaneous and intravenous formulations. The subcutaneous injection comes in 45mg/0.5 mL or 90mg/1 mL solution in a single-dose, prefilled syringe and 45mg/0.5mL solution in a single-dose vial. The intravenous infusion is provided as a 130mg/26 mL (5mg/mL) solution in a single-dose vial.
INDICATIONS
IMPORTANT SAFETY INFORMATION
For more information, see Full Prescribing Information.
About Celltrion, Inc.
Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us. and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook.
About Celltrion USA
Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion's FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA ® (infliximab-dyyb), TRUXIMA ® (rituximab-abbs), HERZUMA ® (trastuzumab-pkrb), VEGZELMA ® (bevacizumab-adcd), YUFLYMA ® (adalimumab-aaty), AVTOZMA ® (tocilizumab-anho), STEQEYMA ® (ustekinumab-stba), STOBOCLO ® (denosumab-bmwo), OSENVELT ® (denosumab-bmwo) and OMLYCLO ® (omalizumab-igec), as well as the novel biologic ZYMFENTRA ® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com and stay updated with our latest news and events on our social media: LinkedIn.
FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", "anticipate" the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries' management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.
Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 hours ago
- Korea Herald
61% of Cybersecurity Professionals Plan AI Adoption as Manufacturing Faces Growing Cyber Risks
Global State of Smart Manufacturing Report finds cybersecurity is now the top external concern after economic conditions MILWAUKEE, Aug. 13, 2025 /PRNewswire/ -- Rockwell Automation, Inc. (NYSE: ROK), the world's largest company dedicated to industrial automation and digital transformation, today released the cybersecurity findings from its 10 th annual " State of Smart Manufacturing Report." Drawing insights from more than 1,500 manufacturing leaders across 17 of the top manufacturing countries, the report reflects how cybersecurity is becoming a central business issue. One third of respondents have direct information technology (IT) and operational technology (OT) cybersecurity responsibilities. As manufacturers advance smart operations, the integration between IT and OT increases the risk of cyberattacks. The report shows that manufacturers are beginning to use artificial intelligence (AI) to help manage these risks to strengthen protection. "Cybersecurity is no longer just a technology issue — it's a boardroom issue," said Stephen Ford, vice president and chief information security officer at Rockwell Automation. "As IT and OT become more connected, the attack surface is expanding. Our latest research confirms what we're seeing firsthand: Cyber risk is now one of the top threats to manufacturing growth. You can't protect tomorrow's enterprise with yesterday's tools. AI is a critical part of the modern security stack, enabling manufacturers to detect threats in real time, maintain productivity, and stay ahead in an increasingly aggressive threat landscape." Key global cybersecurity findings include: Workforce development continues to be a major hurdle. A shortage of skilled talent, training challenges and rising labor costs remain significant barriers to competition. As manufacturers recruit the next generation, cybersecurity and analytical skills are also becoming hiring priorities, reinforcing the need to align technical innovation with human development. "Cybersecurity has become a business enabler," said Ford. "It's no longer just about preventing threats, it's about empowering transformation with confidence. The most forward-thinking manufacturers are proactively leveraging advanced technologies like AI to stay ahead of evolving risks." The full findings of the report can be found here. Methodology Rockwell's 10 th annual State of Smart Manufacturing Report analyzed feedback from 1,560 respondents from 17 of the top manufacturing countries with roles from management up to the C-suite and was conducted in association with Rockwell Automation and Sapio Research. The survey sampled from a range of industries including Consumer Packaged Goods, Food & Beverage, Automotive, Semiconductor, Energy, Life Sciences, and more. With a balanced distribution of company sizes with revenues spanning $100 million to over $30 billion, it offers a wide breadth of manufacturing business perspectives. Note that data and statistics referenced in this release may be sourced from the raw survey data and not included in the report itself.
Korea Herald
3 hours ago
- Korea Herald
25th China International Industry Fair (CIIF) to Spotlight Advanced Manufacturing and Global Collaboration in Shanghai
SHANGHAI, Aug. 13, 2025 /PRNewswire/ -- The 25th China International Industry Fair (CIIF 2025) is set to be held from September 23 to 27 at the National Exhibition and Convention Center in Shanghai. Serving as a platform to advance international industrial cooperation and showcase China's leading intelligent manufacturing solutions, the 2025 tradeshow is expected to attract nearly 3,000 premium enterprises from 30 countries and regions worldwide. Since 1999, the CIIF has played a pivotal role in showcasing the full industrial supply chain, from basic materials and key components to advanced equipment and integrated solutions. It also serves as a hub for SME transformation and consistently brings together top experts to drive industrial and scientific innovation. "The CIIF has witnessed and been promoting the rise of China's industrial development as well as the profound exchanges and integration within the global industrial chain, we're committed to continuously advancing industrial innovation and open international cooperation," said Yao Chunyu, Deputy General Manager of DEXPO Shanghai Industry & Commerce Exhibition Co., Ltd. The 2025 fair will feature nine themed shows, a series of innovation zones, a "1+10+N" conference lineup, a "1+3+Z" award system, creating an international event that integrates technology showcases, business matchmaking, and industry exchange. The Metalworking and CNC Machine Tool Show (MWCS) is a core international metalworking technology trade show under the CIIF umbrella celebrating the innovation in metal processing, focusing on metal-cutting, sheet metal working, metal forming & fabricating, inspecting & measuring, metal 3D printing, advanced functional parts, metallic materials, and more, highlighting exciting developments that can transform global manufacturing practices. Notable exhibitors to attend the 2025 fair include Bodor and Penta Laser. The Industrial Automation Show (IAS), themed "Automation + Industrial AI," will focus on smart manufacturing solutions, automation systems, and industry-specific integration. In 2025, IAS will collaborate with leading companies such as Siemens, Bosch Rexroth, Schneider Electric, Mitsubishi Electric, Omron, Panasonic, and others to unveil new smart manufacturing scenarios. The Robotics Show (RS) will gather global robotics pioneers such as ABB, FANUC, YASKAWA, and KUKA, who will showcase cutting-edge technologies and products. Over 350 exhibitors are expected to display more than 100 new product launches and thousands of industrial devices. This year's edition will feature a dedicated "Humanoid Robot Zone," offering a comprehensive display of the full humanoid ecosystem—from core components to intelligent integration. In addition, CIIF 2025 will also highlight emerging industries including new material, future transportation, AI and more: CIIF not only drives industrial innovation and international cooperation, but also advances market-oriented transformation. As a key platform for global industrial resources and intelligent manufacturing, CIIF 2025 invites professionals from all sectors to join and witness the future of industrial technology.
Korea Herald
6 hours ago
- Korea Herald
Hospital Management Asia 2025: Shaping the Future of Asian Healthcare
HO CHI MINH CITY, Vietnam, Aug. 13, 2025 /PRNewswire/ -- Hospital Management Asia (HMA), the region's premier annual event for hospital management and healthcare, is set to officially take place at GEM Center, Ho Chi Minh City. This year's conference, organised by Clarion Events Pte Ltd, will gather over 100 speakers from 15 countries and territories, alongside hundreds of hospital leaders, medical professionals, and healthcare organizations from across the region and beyond. From Healthcare System Reform to Medical Tourism Under the theme "Quality, Experience & Leadership in Healthcare: Integrate – Inspire – Innovate," HMA 2025 aims to reaffirm core values in modern hospital governance: driving excellence in quality, enhancing patient experience, and fostering strong leadership. The conference officially opens on September 10, 2025, with remarks by Prof. Dr. Tran Van Thuan – Vice Minister of Health, Vietnam, alongside HMA organizing committee representatives. Over the two-day conference, delegates can expect to hear from world-leading experts, including: Dr Lisa Ishii, Senior Vice President (Operations), Johns Hopkins Health System, USA, who will speak on how hospital leadership can be shaped by lessons from the past and innovations in the future. Sasa Mutic – President of Radiation Oncology Solutions, who will be presenting ideas and innovations into accelerating cancer survivorship journeys. There will also be more than 20 in-depth discussion sessions focusing on the three main pillars of: 1. Quality and Safety: infection prevention, AI in diagnosis & treatment, EHR, clinical decision-making; 2. Patient and Staff Experience: healthcare service design, PREMs/PROMs, staff well-being; and 3. Leadership and Organizational Models: Hospital-at-Home, DRG vs FFS business models, ESG, succession strategies, Value-Based Care. Some prominent topics at the conference include medical tourism, a sector where Thailand has established itself as a global leader and economic powerhouse. Leading institutions such as Bumrungrad International Hospital have established Thailand's reputation for excellence, with Artirat Charukitpipat, CEO, Bumrungrad International Hospital, presenting a case study on how the hospital maintains rigorous international accreditation standards while delivering comprehensive medical services. Hospitals also grapple with the ongoing challenges of resource optimization and staff wellbeing while maintaining exceptional patient outcomes. Dr Saran Intakul, Deputy Hospital Director, Samitivej Srinakarin Hospital, will be presenting a compelling case study drawing from real-world experience including his team's exemplary response to the 2024 Singapore Airlines SQ321 turbulence incident that led to an influx of patients to the hospital, demonstrating how strategic workflow preparation and connected care systems enable healthcare facilities to efficiently manage mass-casualty events. Celebrating Innovation and Connecting Practice A notable highlight at HMA 2025 will be two highly anticipated panel sessions on each day of the conference. The " DRG Debate" session will see experts from Malaysia and Thailand's health ministries and associations exchanging opinions in a fiery discussion over the dilemma on whether the Diagnosis-Related Group or Fee-For-Service business model is better-suited to deliver both cost containment and quality care in Southeast Asia's diverse healthcare markets. Meanwhile, the " Vietnam Four" panel session will bring together representatives from four exemplary hospital systems in Vietnam: Hoa Lam Group, FV Hospital, Vinmec International Healthcare System, and Hoan My Medical Corporation. Here, these representatives will share practical experiences and strategies for developing effective hospital models. HMA 2025 wraps up with its highly-anticipated Gala Dinner and the HMA Awards 2025 ceremony, honoring outstanding innovations in hospital management across Asia. Award-winning organizations are recognized as exemplary models of innovation throughout the region. The organizing committee encourages guests to wear traditional national attire, celebrating Asian cultural diversity and fostering multinational connections. Following the main event, on September 12, international delegates will participate in a field visit program to leading hospitals in Ho Chi Minh City: FV Hospital, Gia An 115, City International Hospital, and Tam Anh Hospital. This provides an opportunity for international delegates to directly experience the operational models, treatment protocols, and innovative strategies being implemented in Vietnam. HMA 2025 promises to be a forum for knowledge sharing, professional networking, and creating solutions for the future of Asian healthcare. For more information, please contact:
